Current cancer immunotherapeutic treatment with PD‐1 inhibitors is administered systemically. However, a local treatment strategy may be advantageous as it could provide targeted drug delivery as well as attenuate side… Click to show full abstract
Current cancer immunotherapeutic treatment with PD‐1 inhibitors is administered systemically. However, a local treatment strategy may be advantageous as it could provide targeted drug delivery as well as attenuate side effects seen with systemic treatments. For keratinocyte cancers, where surgical excision is not always applicable, an alternate local treatment approach would be beneficial. This study aims to examine cutaneous pharmacokinetics and biodistribution of the PD‐1 inhibitor nivolumab, locally delivered either by ablative fractional laser (AFL)‐assisted passive diffusion or active intradermal injection, in vivo.
Journal Title: Lasers in Surgery and Medicine
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!